Samsung Invests in Generate Biomedicines for AI Drug Innovation

Samsung announced on December 18th that it will invest in the U.S. biotech venture Generate Biomedicines through its $165 million Life Science Fund, which aims to advance new technologies and business opportunities in the life sciences sector.

The Samsung Life Science Fund, a joint initiative by Samsung C&T, Samsung Biologics, and Samsung Bioepis, is managed by Samsung Ventures. Its goal is to foster innovation and support groundbreaking companies in the biotech field.

Generate Biomedicines specializes in protein design technology powered by generative artificial intelligence (AI) and machine learning. Its proprietary AI platform, Chroma, rapidly designs de novo proteins with desired characteristics, significantly reducing drug development timelines. The company is actively pursuing therapies for cancer, immune disorders, and infectious diseases.

Through this investment, Samsung aims to support Generate Biomedicines’ innovative approach while exploring collaboration opportunities such as contract manufacturing (CMO), co-development projects, and ecosystem development. This partnership aligns with Samsung’s strategy to expand its presence in AI-driven pharmaceutical initiatives.

John Rim, CEO of Samsung Biologics, remarked, “We recognize Generate Biomedicines’ groundbreaking potential in AI-driven therapy development. By leveraging their technology, we aim to advance next-generation pharmaceuticals through collaboration in development, manufacturing, and R&D.”

Mike Nally, CEO of Generate Biomedicines, added, “With partners like Samsung, we aim to enhance our platform, generate high-quality data, and address significant challenges in human health. Over the next 18 months, we plan to initiate three to six new clinical programs, turning technological innovation into real-world solutions.”